Literature DB >> 18195368

Arresting serotonin.

Atheir Abbas1, Bryan L Roth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18195368      PMCID： PMC2242676          DOI： 10.1073/pnas.0711335105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  16 in total

Review 1.  Efficacy at G-protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Nat Rev Drug Discov       Date:  2002-02       Impact factor: 84.694

2.  Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells.

Authors:  J A Gray; D J Sheffler; A Bhatnagar; J A Woods; S J Hufeisen; J L Benovic; B L Roth
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

Review 3.  GPCR functional selectivity has therapeutic impact.

Authors:  Richard B Mailman
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

Review 4.  Beta-arrestin-biased ligands at seven-transmembrane receptors.

Authors:  Jonathan D Violin; Robert J Lefkowitz
Journal:  Trends Pharmacol Sci       Date:  2007-07-20       Impact factor: 14.819

Review 5.  New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors.

Authors:  Robert J Lefkowitz; Keshava Rajagopal; Erin J Whalen
Journal:  Mol Cell       Date:  2006-12-08       Impact factor: 17.970

6.  Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Authors:  David A Shapiro; Sean Renock; Elaine Arrington; Louis A Chiodo; Li-Xin Liu; David R Sibley; Bryan L Roth; Richard Mailman
Journal:  Neuropsychopharmacology       Date:  2003-05-21       Impact factor: 7.853

Review 7.  Hallucinogens.

Authors:  David E Nichols
Journal:  Pharmacol Ther       Date:  2004-02       Impact factor: 12.310

8.  Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.

Authors:  Deborah M Kurrasch-Orbaugh; Val J Watts; Eric L Barker; David E Nichols
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

9.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.

Authors:  K A Berg; S Maayani; J Goldfarb; C Scaramellini; P Leff; W P Clarke
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

10.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.

Authors:  R A Glennon; M Titeler; J D McKenney
Journal:  Life Sci       Date:  1984-12-17       Impact factor: 5.037
View more
  15 in total

1.  Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.

Authors:  John A Allen; Julianne M Yost; Vincent Setola; Xin Chen; Maria F Sassano; Meng Chen; Sean Peterson; Prem N Yadav; Xi-ping Huang; Bo Feng; Niels H Jensen; Xin Che; Xu Bai; Stephen V Frye; William C Wetsel; Marc G Caron; Jonathan A Javitch; Bryan L Roth; Jian Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

2.  Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation.

Authors:  Bryan L Roth
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

Review 3.  Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases.

Authors:  John A Allen; Prem N Yadav; Bryan L Roth
Journal:  Neuropharmacology       Date:  2008-07-02       Impact factor: 5.250

4.  Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity.

Authors:  Ryan T Strachan; Noah Sciaky; Mark R Cronan; Wesley K Kroeze; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2009-11-20       Impact factor: 4.436

5.  Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists.

Authors:  Gitte L Christensen; Christian D Kelstrup; Christina Lyngsø; Uzma Sarwar; Rikke Bøgebo; Søren P Sheikh; Steen Gammeltoft; Jesper V Olsen; Jakob L Hansen
Journal:  Mol Cell Proteomics       Date:  2010-04-02       Impact factor: 5.911

Review 6.  Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Authors:  Leonard L Howell; Kathryn A Cunningham
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function.

Authors:  Jeremy M Veenstra-Vanderweele; Aurelio Galli; Christine Saunders; Michael Siuta; Sabrina D Robertson; Adeola R Davis; Jennifer Sauer; Heinrich J G Matthies; Paul J Gresch; David Airey; Craig W Lindsley; John A Schetz; Kevin D Niswender
Journal:  Neurochem Int       Date:  2013-09-30       Impact factor: 3.921

8.  Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.

Authors:  Xin Chen; Maria F Sassano; Lianyou Zheng; Vincent Setola; Meng Chen; Xu Bai; Stephen V Frye; William C Wetsel; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2012-08-13       Impact factor: 7.446

9.  Cocaine potentiates multiple 5-HT2A receptor signaling pathways and is associated with decreased phosphorylation of 5-HT2A receptors in vivo.

Authors:  Jade M Franklin; Gonzalo A Carrasco
Journal:  J Mol Neurosci       Date:  2014-09-12       Impact factor: 3.444

10.  Full and Partial Agonism of a Designed Enzyme Switch.

Authors:  S Jimmy Budiardjo; Timothy J Licknack; Michael B Cory; Dora Kapros; Anuradha Roy; Scott Lovell; Justin Douglas; John Karanicolas
Journal:  ACS Synth Biol       Date:  2016-07-22       Impact factor: 5.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.